需肾脏替代治疗的社区获得性急性肾损伤及其影响因素的临床研究

    A clinical study on community-acquired acute kidney injury requiring renal replacement therapy and its influencing factors

    • 摘要: 目的 探讨社区获得性急性肾损伤(acute kidney injury,AKI)的临床特点并分析需肾脏替代治疗的影响因素。方法 选取2012年1月至2018年7月在中国科学技术大学附属第一医院肾脏内科住院的社区获得性AKI患者,AKI参照2012年改善全球肾脏病预后组织(Kidney Disease:Improving Global Outcomes,KDIGO)指南标准,根据其住院期间是否行肾脏替代治疗分为未行肾脏替代治疗组和肾脏替代治疗组,比较两组患者入院时临床特征及出院时肾脏预后的差别,采用Logistic回归分析需肾脏替代治疗的影响因素。结果 (1)共纳入237例社区获得性AKI患者,其中AKI 1、2、3期分别占6.3%、11.0%、82.7%,未行肾脏替代治疗组127例,肾脏替代治疗组110例,肾脏替代治疗的比例达到46.4%。(2)社区获得性AKI患者的主要病因有血容量不足、感染、肾毒性物质应用史、梗阻性肾病、慢性肾脏病进展、其他原因,且有50.2%的患者存在两种或两种以上危险因素。(3)多因素Logistic回归分析显示:AKI 3期、院外肾毒性物质的应用史、入院时血钾升高、白细胞计数升高、血红蛋白下降为需肾脏替代治疗的危险因素,病因存在血容量不足则为保护因素,可降低需肾脏替代治疗的风险。结论 临床医师需重视社区获得性AKI患者的病史询问及病因判断,特别是有无肾毒性药物的使用及肾脏灌注不足的因素,关注入院时血钾、白细胞计数、血红蛋白及AKI分期,从而对患者是否需行肾脏替代治疗有进一步的评判,指导后期治疗方案的制定。

       

      Abstract: Objective To investigate the clinical features of community-acquired acute kidney injury (AKI), and analyze the influencing factors of AKI requiring renal replacement therapy. Methods The patients with community-acquired AKI, hospitalized in the Department of Nephrology, The First Affiliated Hospital of USTC from January 2012 to July 2018, were retrospectively enrolled, based on the AKI diagnostic criteria in Kidney Disease:Improving Global Outcomes (KDIGO) Guidelines in 2012. Patients were divided into non-renal replacement therapy group and renal replacement therapy group according to whether renal replacement therapy was performed during hospitalization. The clinical characteristics upon admission and prognosis upon discharge were compared between the two groups. The influencing factors for the requirement for renal replacement therapy were analyzed by Logistic regression. Results (1) A total of 237 community-acquired AKI patients were enrolled, including those with AKI stage 1,2 and 3 accounting for 6.3%, 11.0% and 82.7% respectively. The non-renal replacement therapy group included 127 cases of patients, and the renal replacement therapy group 110 cases of patients. The renal replacement therapy rate was 46.4%. (2) Hypovolemia, infection, history of nephrotoxic drug use, obstructive nephropathy, progression of chronic kidney disease were the main causes of community-acquired AKI. However, 50.2% of patients had two or more risk factors. (3) Multivariate logistic regression analysis showed that AKI stage 3, history of nephrotoxic drug use, and elevated serum potassium, elevated white blood cell count and decreased hemoglobin upon admission were independent risk factors for requirement for renal replacement therapy, while the hypovolemia included in the disease cause was the protective factor which reduced the risk for requiring renal replacement therapy. Conclusions More attention should be paid to the history and etiology of community-acquired AKI patients, especially the use of nephrotoxic drug use and insufficient renal perfusion. Serum potassium, white blood cell count, and hemoglobin upon admission and AKI stages should also be detected, so as to further evaluate whether the patients need renal replacement therapy. Thus, the later treatment plan may be further determined.

       

    /

    返回文章
    返回